Market Place
Sourcing Support
Mustang Bio Exercises Warrants for $4 Million Proceeds
24 Oct 2024 //
GLOBENEWSWIRE
Mustang Bio $2.5M Registered Direct Offering Closed
21 Jun 2024 //
GLOBENEWSWIRE
Mustang Bio Announces $2.5M Direct Offering Priced At-Market Under Nasdaq Rules
20 Jun 2024 //
GLOBENEWSWIRE
Mustang Bio Announces Data From Phase 1/2 Trial Of MB-106 CAR-T Therapy In WM
17 Jun 2024 //
GLOBENEWSWIRE
Mustang Bio Announces Closing of $4 Million Public Offering
02 May 2024 //
GLOBENEWSWIRE
Mustang Bio Announces Pricing of $4 Million Public Offering
29 Apr 2024 //
GLOBENEWSWIRE
Mustang Bio to lay off workers; MaaT`s new data for microbiome therapy
15 Apr 2024 //
ENDPTS
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform
28 Mar 2024 //
GLOBENEWSWIRE
CAR-T for brain cancer extends survival in phase 1 trial
12 Mar 2024 //
FIERCE BIOTECH
Mustang Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
11 Mar 2024 //
GLOBENEWSWIRE
Mustang Bio to Participate in B. Riley Securities 4th Annual Oncology Conference
11 Jan 2024 //
GLOBENEWSWIRE
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106
11 Dec 2023 //
GLOBENEWSWIRE
Mustang Bio Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation
02 Nov 2023 //
GLOBENEWSWIRE
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering
30 Oct 2023 //
GLOBENEWSWIRE
Mustang Bio Announces FDA Acceptance of IND Application for MB-109
26 Oct 2023 //
GLOBENEWSWIRE
Mustang Bio Announces $4.4 Million Registered Direct Offering
26 Oct 2023 //
GLOBENEWSWIRE
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
07 Sep 2023 //
GLOBENEWSWIRE
Mustang Announces First Data from Multicenter Phase 1/2 Trial Evaluating MB-106
16 Aug 2023 //
GLOBENEWSWIRE
Mustang Bio Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Mustang Bio to Participate in Two August 2023 Investor Conferences
03 Aug 2023 //
GLOBENEWSWIRE
Mustang Bio Announces Closing of Partnership Transaction with uBriGene
31 Jul 2023 //
GLOBENEWSWIRE
Mustang Bio Announces Participation in Upcoming Scientific Meetings
06 Jul 2023 //
GLOBENEWSWIRE
Mustang Bio Announces FYR from Follicular Lymphoma Ph1/2 Trial of MB-106, CD20
15 Jun 2023 //
GLOBENEWSWIRE
Mustang Bio Announces Results from Ongoing Phase 1/2 Clinical Trial of MB-106
12 Jun 2023 //
GLOBENEWSWIRE
Mustang Bio to sell Massachusetts CAR-T manufacturing facility
18 May 2023 //
ENDPTS
Mustang bucks some partnered cell, gene therapies
18 May 2023 //
FIERCE BIOTECH
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
18 May 2023 //
GLOBENEWSWIRE
Mustang Bio Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Mustang Announces Presentations of Clinical Data from Phase 1/2 Trial of MB-106
11 May 2023 //
GLOBENEWSWIRE
Mustang Bio Announces Reverse Stock Split
03 Apr 2023 //
GLOBENEWSWIRE
Mustang Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
29 Mar 2023 //
GLOBENEWSWIRE
Mustang Bio to Participate in Cantor The Future of Oncology Virtual Symposium
28 Mar 2023 //
GLOBENEWSWIRE
Mustang Bio to Participate in the B. Riley Securities Annual Oncology Conference
17 Jan 2023 //
GLOBENEWSWIRE
Mustang Provides CAR T Cell Therapy Portfolio Updates and Anticipated Milestones
19 Dec 2022 //
GLOBENEWSWIRE
Mustang Bio Reports 3Q 2022 Financial Results and Recent Corporate Highlights
14 Nov 2022 //
GLOBENEWSWIRE
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106
27 Oct 2022 //
GLOBENEWSWIRE
Mustang Announces First Patient Treated in Multicenter Phase 1/2 Trial of MB-106
06 Oct 2022 //
GLOBENEWSWIRE
Mustang Bio Reports Q2 2022 Rusult and Recent Corporate Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Mustang Bio Successfully Treats Patient by Ex Vivo Lentiviral Gene Therapy
27 Jul 2022 //
GLOBENEWSWIRE
Mustang Bio Announces ODD Granted to MB-106
22 Jun 2022 //
GLOBENEWSWIRE
Mustang Bio Announces Updated Results from FL Cohort of PI/II Trial of MB-106
13 Jun 2022 //
GLOBENEWSWIRE
Mustang Bio`s Updated Interim Data on X-Linked Severe Combined Immunodeficiency
19 May 2022 //
GLOBENEWSWIRE
Mustang Bio: Results from Follicular Lymphoma Cohort of PI/II Trial of MB-106
12 May 2022 //
GLOBENEWSWIRE
Mustang Bio Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Mustang Bio Announces Data on Lentiviral Viral Vector Gene Therapy
03 May 2022 //
GLOBENEWSWIRE
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
21 Apr 2022 //
GLOBENEWSWIRE
Mustang Bio Announces PI Trial Combining MB-101 and MB-108 for Glioblastoma
13 Apr 2022 //
GLOBENEWSWIRE
Mustang Bio to Present at Virtual Fortress Biotech R&D Summit
04 Apr 2022 //
GLOBENEWSWIRE
Mustang Bio Reports Full-Year 2021 Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
Mustang Bio to Participate in Three March 2022 Investor Conferences
10 Mar 2022 //
GLOBENEWSWIRE
Mustang Bio`s Abstract Accepted for Late-Breaker Poster Presentation at AACR
09 Mar 2022 //
GLOBENEWSWIRE
Mustang Bio Completes a $75 M Debt Financing with Runway Growth Capital
08 Mar 2022 //
GLOBENEWSWIRE
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data
15 Feb 2022 //
GLOBENEWSWIRE
FDA slams door to pivotal trial for bubble boy disease gene therapy
26 Jan 2022 //
ENDPTS
Mustang Bio Provides an Update on its IND Application for MB-207 in XSCID
24 Jan 2022 //
GLOBENEWSWIRE
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data
07 Jan 2022 //
GLOBENEWSWIRE
Mustang Bio Added to the NASDAQ Biotechnology Index
16 Dec 2021 //
GLOBENEWSWIRE
Mustang Bio to Host Key Opinion Leader Webinar on MB-106
09 Dec 2021 //
GLOBENEWSWIRE
